Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 02/05/21 | 4 | Statement of changes in beneficial ownership of securities |
|
2 | |
| 01/29/21 | 8-K | Current report filing |
|
   |
9 |
| 01/22/21 | EFFECT | Notice of Effectiveness |
|
1 | |
| 01/21/21 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 01/21/21 | UPLOAD | SEC-generated letter |
|
1 | |
| 01/15/21 | S-3 | Registration statement for specified transactions by certain issuers |
|
27 | |
| 01/08/21 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
70 |
| 12/30/20 | EFFECT | Notice of Effectiveness |
|
1 | |
| 12/30/20 | S-3/A | Registration statement for specified transactions by certain issuers |
|
6 | |
| 12/29/20 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 |
